{
  "trial_id": "NCT01377844",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, body mass index (BMI), baseline HbA1c, fasting plasma glucose (FPG), blood pressure (systolic and diastolic), body weight, duration of diabetes, use of anti-diabetic medication, use of anti-hypertensive medication, use of lipid modifying therapy, eGFR, liver function tests (ALT, AST, bilirubin), history of genitourinary tract infections, history of kidney stones, presence of retinopathy or nephropathy, hypertension status, heart failure status, HIV status, HCV status, drug screen results, participation in other trials, previous treatment with EGT0001442 or EGT0001474.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Body Mass Index",
          "body mass index (BMI)"
        ],
        [
          "Baseline HbA1c Category",
          "baseline HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "fasting plasma glucose (FPG)",
        "blood pressure (systolic and diastolic)",
        "body weight",
        "duration of diabetes",
        "use of anti-diabetic medication",
        "use of anti-hypertensive medication",
        "use of lipid modifying therapy",
        "eGFR",
        "liver function tests (ALT, AST, bilirubin)",
        "history of genitourinary tract infections",
        "history of kidney stones",
        "presence of retinopathy or nephropathy",
        "hypertension status",
        "heart failure status",
        "HIV status",
        "HCV status",
        "drug screen results",
        "participation in other trials",
        "previous treatment with EGT0001442 or EGT0001474"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Baseline HbA1c, Fasting Plasma Glucose, Blood Pressure, Anti-diabetic medication use, Anti-hypertensive medication use, Lipid modifying therapy use, eGFR,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Body Mass Index",
          "Body Mass Index"
        ],
        [
          "Baseline HbA1c Category",
          "Baseline HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Fasting Plasma Glucose",
        "Blood Pressure",
        "Anti-diabetic medication use",
        "Anti-hypertensive medication use",
        "Lipid modifying therapy use",
        "eGFR"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, HbA1c, Fasting Plasma Glucose, Systolic Blood Pressure, Diastolic Blood Pressure, Diabetes Duration, Anti-diabetic Medication Use, Lipid Modifying Therapy Use, Anti-hypertensive Medication Use.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Body Mass Index",
          "Body Mass Index"
        ],
        [
          "Baseline HbA1c Category",
          "HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Fasting Plasma Glucose",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Diabetes Duration",
        "Anti-diabetic Medication Use",
        "Lipid Modifying Therapy Use",
        "Anti-hypertensive Medication Use"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, BMI, HbA1c, FPG, systolic blood pressure, diastolic blood pressure, body weight, diabetes duration, type of anti-diabetic medication, type of anti-hypertensive medication, type of lipid modifying therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Body Mass Index",
          "BMI"
        ],
        [
          "Baseline HbA1c Category",
          "HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "FPG",
        "systolic blood pressure",
        "diastolic blood pressure",
        "body weight",
        "diabetes duration",
        "type of anti-diabetic medication",
        "type of anti-hypertensive medication",
        "type of lipid modifying therapy"
      ]
    }
  }
}